Adagene_Logo_GNW.png
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
16 janv. 2024 17h01 HE | Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
22157.jpg
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
22 nov. 2023 08h58 HE | Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
New Logo.png
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
15 nov. 2023 09h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
22 oct. 2023 06h01 HE | HOOKIPA Pharma Inc.
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...
metastatic-cancer-drugs-market-size.jpg
Metastatic Cancer Drug Market Thrives with Collaborative Innovations: Pfizer, Sanofi, and Merck Leading the Charge
15 sept. 2023 10h18 HE | Research and Markets
Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted...
7 Hills Logo.png
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
22 mai 2023 13h05 HE | 7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Global Checkpoint Inhibitors Market
Global Checkpoint Inhibitors Market Report 2023: Rising Number of Cancer Cases Drives Growth
24 avr. 2023 13h18 HE | Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
22157.jpg
Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast 2022 - 2032
06 avr. 2023 05h03 HE | Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.This...
New Logo.png
Provectus Biopharmaceuticals Releases 2023 Stockholder Letter
09 janv. 2023 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found...
head-and-neck-cancer-therapeutics-market-size.jpg
Global Head And Neck Cancer Therapeutics Market Report 2022: Featuring Eli Lilly, Merck, Sanofi, Takeda Pharmaceutical & More
09 janv. 2023 07h48 HE | Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and...